Form 4 for ACAD ACADIA PHARMACEUTICALS INC
Accepted 2023-05-02 00:00:00 ET · period of report 2023-04-29 · accession 0001209191-23-026742 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2023-05-02 | 2023-04-29 | ACAD | DAVIS STEPHEN | CEO, Dir | M - OptEx | $0.00 | +15.6K | 116.1K | +16% | $0 |
| D | 2023-05-02 | 2023-05-01 | ACAD | DAVIS STEPHEN | CEO, Dir | S - Sale+OE | $21.18 | -7,806 | 108.3K | -7% | -$165.3K |
| D | 2023-05-02 | 2023-04-29 | ACAD | DAVIS STEPHEN | CEO, Dir | M - OptEx | $0.00 | -15.6K | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-04-29 | M | A | 15,625 | $0.00 | 116,103 | D | — | — | |
| 2 | Common | Common Stock | 2023-05-01 | S | D | 7,806 | $21.18 | 108,297 | D | — | — | |
| 3 | Derivative | Restricted Stock Units | 2023-04-29 | M | D | 15,625 | $0.00 | 0 | D | — · — to — | 15,625 Common Stock | (F2) Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. (F3) The restricted stock units vest in four equal annual installments beginning April 29, 2020. |